ArticleHereditas2025
Reduced miR-338-3p contributes to polycystic ovarian syndrome by inhibiting proliferation and enhancing apoptosis.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interconnected cell death pathways: central mechanisms and therapeutic targets in impaired follicular development of polycystic ovary syndrome.Journal of ovarian research · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPolycystic ovarian syndrome (PCOS) is a frequently occurring disorder affecting reproductive and metabolic health. miR-338-3p is implicated in early follicular development. We aimed to investigate the expression of miR-338-3p in PCOS patients and its effects on proliferation and apoptosis of ovarian granulosa cells.
methodsThe study included 100 healthy women and 110 women diagnosed with PCOS as participants. Reverse transcription quantitative PCR (RT-qPCR) was used to detect the expression of miR-338-3p and phosphatase and tensin homolog (PTEN), and receiver operating characteristic (ROC) was employed to evaluate the diagnostic efficacy of miR-338-3p. Cell proliferation and apoptosis were detected by Cell Counting Kit-8 (CCK-8) and flow cytometry. Pearson correlation analysis was used to assess the correlations between miR-338-3p and luteinizing hormone (LH), testosterone, or PTEN. The target relationship of miR-338-3p and PTEN was confirmed via dual-luciferase assay.
resultsSerum miR-338-3p was decreased in PCOS patients, and it was negatively correlated with both LH and testosterone. Downregulation of miR-338-3p inhibits the proliferation of ovarian granulosa cells and enhances cell apoptosis, whereas upregulation produces the opposite effect. PTEN inhibition subverted the inhibited proliferation and enhanced apoptosis regulated by miR-338-3p inhibitor.
conclusionsReduced miR-338-3p levels have potential predictive value in distinguishing individuals with PCOS patients from normal population. Mechanistically, this microRNA regulates the PTEN gene to inhibit granulosa cell proliferation and promote apoptosis, thereby contributing to the pathological processes of PCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.